Our Company was incorporated on February 22, 1996 under the Companies Act, 1956, with the Registrar of Companies, Punjab, Himachal pradesh and Chandigarh. For details of change in our Registered Office, see History and Certain Corporate Matters on page 129 of the Prospectus. Registered Office: S.C.O. 99-100, Top Floor, Sector 17-B, Chandigarh 160 017, India. Tel: + (91 172) 391 4646; Fax: + (91 172) 391 4645. There has been no change in the name of our Company since incorporation. Company Secretary and Compliance Officer: Mr. Anil Kumar; Email: pdl.ipo@parabolicdrugs.com; Website: www.parabolicdrugs.com

PUBLIC ISSUE OF 2,66,66,667 EQUITY SHARES OF FACE VALUE RS.10 EACH (THE EQUITY SHARES) OF PARABOLIC DRUGS LIMITED (OUR COMPANY OR THE ISSUER) FOR CASH AT A PRICE OF RS.75 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF RS.65 PER EQUITY SHARE) AGGREGATING TO RS.200,00,00,025 (THE ISSUE). THE ISSUE COMPRISES A NET ISSUE OF 2,61,66,667 EQUITY SHARES (THE NET ISSUE) AND A RESERVATION OF 5,00,000 EQUITY SHARES FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE EMPLOYEE RESERVATION PORTION). THE ISSUE COMPRISES A FRESH ISSUE OF 2,46,40,965 EQUITY SHARES BY OUR COMPANY (THE FRESH ISSUE) AND AN OFFER FOR SALE OF 20,25,702 EQUITY SHARES (OFFER FOR SALE) BY BTS INDIA PRIVATE EQUITY FUND LIMITED AND ALDEN GLOBAL (MAURITIUS) LIMITED (TOGETHER,THE SELLING SHAREHOLDERS). THE ISSUE CONSTITUTED 43.09% OF THE FULLY DILUTED POST ISSUE PAIDUP CAPITAL OF OUR COMPANY.

The Equity Shares of the Company are proposed to be listed on Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE) and the trading is expected to commence on July 1, 2010.
THE FACE VALUE PER EQUITY SHARE IS RS.10/-
THE ISSUE PRICE PER EQUITY SHARE IS RS.75/- AND IT IS 7.5 TIMES THE FACE VALUE.
The Issue was made through the book building process (the Book Building Process) wherein up to 50% of the Net Issue was available for allocation on a proportionate basis to Qualified Institutional Buyers (QIBs) (the QIB Portion). Further 5%of the QIB Portion was available for allocation on a proportionate basis to Mutual Funds only. The remainder was available for allocation on a proportionate basis to QIBs and Mutual Funds, subject to valid Bids being received from them at or above the Issue Price. Further, not less than 15% of the Net Issue was available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue was available for allocation on a proportionate basis to Retail Individual Bidders, subject to valid Bids being received at or above the Issue Price. Further, 5,00,000 Equity Shares was made available for allocation on a proportionate basis to the Eligible Employees, subject to valid Bids being received at or above the Issue Price.
The Issue received 12,111 applications (after cheque return cases) for 27,436,880 equity shares resulting in 1.029 times subscription. The details of the applications received in the Issue from Qualified institutional Buyers, Non-Institutional, Retail Individual Investor and Employee categories are as under: (Before technical rejections)

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/Issue Closing date at different bid prices is as under:

The Basis of Allocation was finalized in consultation with the Designated Stock Exchange, being the Bombay Stock Exchange Limited (BSE) on June 25, 2010

A. Allocation to Employee Investors (After Technical Rejections) includes ASBA Applications

The Basis of Allocation to the Employee Investors, who have bid at cut off and the Issue Price of Rs.75/- per Equity Share, was finalized in consultation with BSE. The category was subscribed 0.0995 times. As per the Prospectus, the spill over portion to the extent of 450,240 equity shares has been added to Retail Category (157,584 Equity Shares), Non Institutional Investor Category (67,536 Equity Shares) and QIB Category (225,120 Equity Shares).The total number of shares allotted in this category is 49,760 Equity Shares to 81 successful applicants. The category-wise details of the Basis of Allocation are as under:

B. Allocation to Retail Individual Investors (After Technical Rejections) includes ASBA Applications

The Basis of Allocation to the Retail Individual Investors; who have bid at cut off and the Issue Price of Rs.75/- per Equity Share was finalized in consultation with BSE. The category was subscribed 0.356 times. As per the Prospectus, the spill over portion to the extent of 60,03,758 equity shares has been added to Non Institutional Investor Category (1,385,483 Equity Shares), and QIB Category (4,618,275 Equity Shares). The total number of shares allotted in this category is 3,312,160 Equity Shares to 11,663 successful applicants including spill over from Employee Category (157,584 Equity Shares). The category-wise details of the Basis of Allocation are as under:

C. Allocation to Non Institutional Investors (After Technical Rejections) includes ASBA Applications

The Basis of Allocation to the Non Institutional Investors, who have bid at the issue Price of Rs.75/- per Equity Share, was finalized in consultation with BSE. The category was subscribed 0.864 times. As per the Prospectus, the spill over portion to the extent of 732,659 equity shares has been added to QIB Category (732,659 Equity Shares). The total number of shares allotted in this category is 4,645,360 Equity Shares to 24 successful applicants including spill over from Employee Category (67,536 Equity Shares) and Retail Category (1,385,483 Equity Shares). The category-wise details of the Basis of Allocation are as under:

D. Allocation to QIBs (After Technical Rejections) includes ASBA Applications

Allocation to QIBs has been done on a proportionate basis in consultation with BSE. As per the SEBI regulations, Mutual Funds were initially allotted 5% of the quantum of shares available (932,968 Equity Shares to 11 successful applicant) including spill over from Employee Category (11,256 Equity Shares), Retail Category (230,913 Equity Shares) and Non Institutional Category (36,633 Equity Shares) and other QIBs were allotted the remaining available shares (17,726,419 Equity Shares to 22 successful applicants) including spill over from Employee Category (213,864 Equity Shares), Retail Category (4,387,362 Equity Shares) and Non Institutional Category (696,026 Equity Shares) on proportionate basis,

The Board of Directors of the company at its Meeting held at Chandigarh, on 26th June 2010 has approved the basis of allocation of shares of the Issue and has allotted the shares to various successful applicants.

The CAN-cum-Refund Orders and allotment advice and notices has been dispatched on June 28, 2010 to the address of the investors as registered with the depositories. In case the same is not received within ten days, investors may contact at the address given below. The Refund Orders have been over-printed with the Bank Mandate details as registered, if any, with the depositories. The shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The company is taking steps to get the equity shares admitted for trading on Bombay Stock Exchange Limited and the National Stock Exchange of India Limited within twelve working days from the date of closure of the issue.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the prospectus dated June 24, 2010 (Prospectus)

INVESTORS PLEASE NOTE

This details of the allocation made would be hosted on the website of Registrars to the issue, Link Intime India Private Limited at http://www.linkintime.co.in

All future correspondence in this regard may kindly be addressed to the Registrars to the issue quoting full name of the First/Sole applicant, Serial number of the bid-cum-application form, number of shares bid for, name of the Member of the Syndicate and Place where the bid was submitted and payment details at the address given below:

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF PARABOLIC DRUGS LIMITED